Click on the panels below to find out more about our latest hosted content
This resource provides information on the management of patients with adult ADHD.Contains promotional content for UK Healthcare Professionals.Click here for Prescribing Information and Adverse Event Reporting.Job code: C-APROM/UK/ELVA/0062Date of Preparation: March 2021Initiated, developed and funded by Takeda Pharmaceuticals Limited.
This resource provides information on the management of patients with hereditary angioedema.Initiated and funded by Takeda UK Limited.
Click here for Prescribing Information and Adverse Event Reporting
Job code: C-APROM/UK/TAKH/0026Date of preparation: May 2021
This information is intended for UK healthcare professionals only.For prescribing information, click here.Job code: UK/M001/0761, December 2019
A survey of 710 people with rosacea and 554 doctors has revealed valuable insights on the invisible impact of a visible disease for the patients and the community. It is time to fight back against stereotypes and talk openly about rosacea burden.
This resource is intended for UK healthcare professionals only and provides promotional information on the management of adult patients with CLL. Job code: UK-VNCCLL-210083 Date of preparation: March 2021
For UK healthcare professionals only. The Iron Deficiency Anaemia Resource is designed for healthcare professionals who manage patients with chronic kidney disease, congestive heart failure, inflammatory bowel disease or those listed for major elective surgery.
Click here for Prescribing Information
Job code: UK-MONF-1019-00008Date of preparation: Oct 2020
Please click here for adverse event reporting and prescribing information (included at the bottom of the page)Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
Intended for UK/IE healthcare professionalsThis content is promotional and has been developed and sponsored by Lilly1. Trulicity Summary of Product Characteristics.PP-DG-GB-0646 November 2020© 2020 Eli Lilly and Company. All rights reserved.Trulicity® and Lilly are registered trademarks of Eli Lilly and Company.
This resource provides videos from our atopic dermatitis (AD) mechanism of action series, further information on Olumiant, as well as a downloadable prescribers guide and patient guide.This promotional content has been developed, organised and funded by Eli Lilly and Company and is intended for UK healthcare professionals only.
Job code: PP-BA-GB-0729
Date of preparation: January 2021
This contains promotional information regarding the management of patients with ChronicLymphocytic Leukaemia (CLL) and is intended for use by UK Health Care Professionals only.
Date of Preparation: December 2020Job Code: CP-198204
This resource contains promotional information regarding the treatment of adults with wet age-related macular degeneration (AMD).
This promotional content has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.
UK | April 2021 | 109634
This resource was initiated and funded by Pfizer Ltd and it contains promotional content for UK healthcare professionals.
Please click here for Prescribing Information and Adverse Event reporting
PP-REF-GBR-0249 | May 2021
Hear from Dr Nick Panay(Consultant Gynaecologist and Director of the West London Menopause and PMS Centre),Dr Jane F Wilkinson(GP and Clinical Director of Menopause Wellbeing)and Dr Shahzadi Harper(GP and founder of the Harper Clinic)This page and these videos have been developed and funded by Besins Healthcare (UK) Ltd, are intended for healthcare professionals only and contain promotional content. OES/2021/006 | May 2021
Learn more about Galapagos, and our sponsored activities during ECCO.
Intended for Healthcare professionals. This programme is not affiliated with ECCO.
Code: GL-IBD-NA-202105-00016 Date of Preparation: May 2021
The Numbers that Matter Report challenges current practices in ITP management of focusing on platelet count and advocates the need to improve conversations with those affected by the disease. It is time to stop counting and start asking about the numbers that matter most to patientsJune 2021 | 124612